Patents Assigned to Eccogene (Shanghai) Co., Ltd.
  • SSAO inhibitors and use thereof
    Patent number: 11964942
    Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease in which SSAO plays a role.
    Type: Grant
    Filed: May 5, 2022
    Date of Patent: April 23, 2024
    Assignee: Eccogene (Shanghai) Co., Ltd.
    Inventors: Zaifang Ren, Xuefeng Sun, Qing Xu
  • Thyroid hormone receptor agonists and use thereof
    Patent number: 11780825
    Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of thyroid hormone receptors, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease or disorder regulated by thyroid hormone.
    Type: Grant
    Filed: January 13, 2021
    Date of Patent: October 10, 2023
    Assignee: Eccogene (Shanghai) Co., Ltd.
    Inventors: Jingye Zhou, Jiuxiang Zhu, Mingwei Zheng
  • Substituted imidazoles as GLP-1 receptor agonists
    Patent number: 11584751
    Abstract: The application relates to a compound of Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of GLP-1 receptor, a pharmaceutical composition comprising a compound of Formula (I), and a method of treating or preventing a disease in which GLP-1 receptor plays a role.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: February 21, 2023
    Assignee: Eccogene (Shanghai) Co., Ltd.
    Inventors: Zaifang Ren, Xuefeng Sun, Jingye Zhou, Qing Xu
  • SSAO inhibitors and use thereof
    Patent number: 11472769
    Abstract: The application relates to a compound of Formula (I?) or (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of Formula (I?) or (I), and a method of treating or preventing a disease in which SSAO plays a role.
    Type: Grant
    Filed: October 28, 2020
    Date of Patent: October 18, 2022
    Assignee: Eccogene (Shanghai) Co., Ltd.
    Inventors: Zaifang Ren, Xuefeng Sun, Qing Xu